Literature DB >> 31809637

Polysaccharide PCP-I isolated from Poria cocos enhances the immunogenicity and protection of an anthrax protective antigen-based vaccine.

Kun Liu1, Ying Yin1, Jun Zhang1, Xiaodong Zai1, Ruihua Li1, Hao Ma2, Junjie Xu1, Junjie Shan2, Wei Chen1.   

Abstract

Polysaccharides isolated from natural plants may represent a novel source of vaccine adjuvants. In this research, we focused on a natural plant polysaccharide, PCP-I, which is derived from Poria cocos, a Chinese traditional herbal medicine. We chose the anthrax protective antigen (PA) as a model to evaluate the adjuvant ability of PCP-I in enhancing the immunogenicity and protection of a PA-based anthrax vaccine. According to our results, PCP-I could significantly enhance anthrax specific anti-PA antibodies, toxin-neutralizing antibodies, anti-PA antibody affinity, as well as IgG1 and IgG2a levels. Besides, PCP-I increased the frequency of PA-specific memory B cells, increased the proliferation of PA-specific splenocytes, significantly stimulated the secretion of IL-4, and enhanced the activation of Dendritic cells (DCs) in vitro. The combination of PCP-I and CpG significantly enhanced the level of anti-PA antibodies and neutralizing antibodies, particularly PA-specific IgG2a, and shifted the Th2-bias to a Th1/Th2 balanced response. In addition, PCP-I with or without CpG could significantly improve the survival rate of immunized mice following challenge with the anthrax lethal toxin. These findings suggest that PCP-I may be a promising vaccine adjuvant that warrants further study.

Entities:  

Keywords:  Poria cocos ; Polysaccharide; anthrax; protective antigen; vaccine adjuvant

Mesh:

Substances:

Year:  2019        PMID: 31809637      PMCID: PMC7482710          DOI: 10.1080/21645515.2019.1675457

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  27 in total

1.  Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.

Authors:  Vladimir Savransky; Jeffry D Shearer; Melicia R Gainey; Daniel C Sanford; Gloria S Sivko; Gregory V Stark; Na Li; Boris Ionin; Michael J Lacy; Mario H Skiadopoulos
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 3.641

2.  Engineering biomaterial-associated complement activation to improve vaccine efficacy.

Authors:  Yuan Liu; Ying Yin; Lianyan Wang; Weifeng Zhang; Xiaoming Chen; Xiaoxiao Yang; Junjie Xu; Guanghui Ma
Journal:  Biomacromolecules       Date:  2013-08-05       Impact factor: 6.988

3.  The polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions.

Authors:  Peter D Cooper; Thomas G Barclay; Milena Ginic-Markovic; Nikolai Petrovsky
Journal:  Glycobiology       Date:  2013-07-12       Impact factor: 4.313

4.  Deletion modification enhances anthrax specific immunity and protective efficacy of a hepatitis B core particle-based anthrax epitope vaccine.

Authors:  Ying Yin; Sheng Zhang; Chenguang Cai; Jun Zhang; Dayong Dong; Qiang Guo; Ling Fu; Junjie Xu; Wei Chen
Journal:  Immunobiology       Date:  2013-08-23       Impact factor: 3.144

Review 5.  Applications of Immunomodulatory Immune Synergies to Adjuvant Discovery and Vaccine Development.

Authors:  Janine K Tom; Tyler J Albin; Saikat Manna; Brittany A Moser; Rachel C Steinhardt; Aaron P Esser-Kahn
Journal:  Trends Biotechnol       Date:  2018-11-21       Impact factor: 19.536

Review 6.  Dendritic cells: arbiters of immunity and immunological tolerance.

Authors:  Kanako L Lewis; Boris Reizis
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-08-01       Impact factor: 10.005

Review 7.  Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity.

Authors:  Shuting Shi; Haoru Zhu; Xinyu Xia; Zhihui Liang; Xuehu Ma; Bingbing Sun
Journal:  Vaccine       Date:  2019-04-29       Impact factor: 3.641

8.  An α-glucan isolated from root of Isatis Indigotica, its structure and adjuvant activity.

Authors:  Junjie Shan; Guohui Sun; Jinwei Ren; Ting Zhu; Peiyuan Jia; Wensheng Qu; Qian Li; Junhua Wu; Hao Ma; Song Wen; Yuxia Wang
Journal:  Glycoconj J       Date:  2014-04-29       Impact factor: 2.916

9.  Improving the stability of recombinant anthrax protective antigen vaccine.

Authors:  Anita Verma; Drusilla L Burns
Journal:  Vaccine       Date:  2018-09-15       Impact factor: 3.641

10.  Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal Bacillus anthracis spore inhalation challenge.

Authors:  Genevieve M Weir; Lisa D MacDonald; Rajkannan Rajagopalan; Gloria S Sivko; Michelle W Valderas; Jonathan Rayner; Bradley J Berger; Leeladhar Sammatur; Marianne M Stanford
Journal:  NPJ Vaccines       Date:  2019-02-08       Impact factor: 7.344

View more
  2 in total

1.  Poria cocos polysaccharide induced Th1-type immune responses to ovalbumin in mice.

Authors:  Xiaoxiao Dong; Boye Li; Boyang Yu; Tian Chen; Qin Hu; Bo Peng; Wang Sheng
Journal:  PLoS One       Date:  2021-01-07       Impact factor: 3.240

2.  Immune-Enhancing Activity of Aqueous Extracts from Artemisia rupestris L. via MAPK and NF-kB Pathways of TLR4/TLR2 Downstream in Dendritic Cells.

Authors:  Yu Yang; DanYang Wang; QuanXiao Li; Jiang He; Bin Wang; Jinyao Li; Ailian Zhang
Journal:  Vaccines (Basel)       Date:  2020-09-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.